HomeCompareEPZM vs GBDC

EPZM vs GBDC: Dividend Comparison 2026

EPZM yields 136.05% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $5.38M in total portfolio value· pulled ahead in Year 10
10 years
EPZM
EPZM
● Live price
136.05%
Share price
$1.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$15.39M
Annual income
$6,293,323.05
Full EPZM calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — EPZM vs GBDC

📍 GBDC pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEPZMGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EPZM + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EPZM pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPZM
Annual income on $10K today (after 15% tax)
$11,564.63/yr
After 10yr DRIP, annual income (after tax)
$5,349,324.59/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $8,581,549.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPZM + GBDC for your $10,000?

EPZM: 50%GBDC: 50%
100% GBDC50/50100% EPZM
Portfolio after 10yr
$18.08M
Annual income
$11,341,293.23/yr
Blended yield
62.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPZM right now

EPZM
Analyst Ratings
10
Buy
5
Hold
1
Sell
Consensus: Buy
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPZM buys
0
GBDC buys
0
No recent congressional trades found for EPZM or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEPZMGBDC
Forward yield136.05%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$15.39M$20.78M
Annual income after 10y$6,293,323.05$16,389,263.41
Total dividends collected$14.14M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: EPZM vs GBDC ($10,000, DRIP)

YearEPZM PortfolioEPZM Income/yrGBDC PortfolioGBDC Income/yrGap
1$24,305$13,605.44$12,490$1,790.28+$11.8KEPZM
2$56,912$30,905.26$16,522$3,157.73+$40.4KEPZM
3$128,528$67,631.59$23,578$5,898.68+$105.0KEPZM
4$280,268$142,743.86$37,115$11,886.75+$243.2KEPZM
5$590,792$290,905.24$66,136$26,423.57+$524.7KEPZM
6$1,205,245$573,097.64$137,257$66,491.44+$1.07MEPZM
7$2,382,274$1,092,661.12$341,734$194,868.54+$2.04MEPZM
8$4,567,482$2,018,449.47$1,050,788$685,133.02+$3.52MEPZM
9$8,503,963$3,616,756.90$4,099,314$2,974,971.01+$4.40MEPZM
10← crossover$15,392,564$6,293,323.05$20,775,530$16,389,263.41$5.38MGBDC

EPZM vs GBDC: Complete Analysis 2026

EPZMStock

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..

Full EPZM Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this EPZM vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPZM vs SCHDEPZM vs JEPIEPZM vs OEPZM vs KOEPZM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.